We did a thing! https://t.co/U9H9LH2Pmb
This review, which is part of a themed collection on axially chirality, was written with the goal of sharing some fundamentals and capturing a 'snapshot' of the state of atropisomerism in drug discovery.
One thing worth mentioning is the majority of examples utilized tried and true chiral resolution chemistry, however there was a lot of innovation in recycling of the unwanted atropisomer. There were also a few examples of asymmetric catalysis being employed.
Excited to announce that the preliminary program for the 2027 Gordon Research Conference on Heterocyclic Compounds, June 20–25 in Newport, RI, is online!
https://t.co/NnW86efApu
We have an outstanding lineup of academic and industry scientists. Hope to see many of you there!
a successful beach day (most) of the organic chemistry groups along with a PhDs vs Candidates volleyball match! (a few injuries, no deaths) @GustafsonLab@jillalty@barneygrubbs@QJBruch Prof. Katherine Aubrecht and Prof. Matthew Parkers Group
The S-Atropisomer* had no KIT activity, but displayed intriguing selectivity towards LYN kinase, an emerging target for the treatment of cancer, autoimmune diseases and inflammatory conditions, that currently lacks highly selective inhibitors.
Another day another preprint on ChemRxiv!
“Leveraging Atropisomerism to Obtain a Mutant-Selective c-KIT Inhibitor in Gastrointestinal Stromal Tumors”
A story of privileged heterocycles, atropisomerism and kinase selectivity.
https://t.co/tlSyYPLCQT
The R-atropisomer* maintained potency against cellular models of GIST (IC50 < 10 nM) while displaying improved target selectivity, including towards key oncogenic c-KIT mutants. *Cahn-Ingold-Prelog priorities cause the analogs to have opposite stereochemical descriptors.*
This led us to introduce a peri Fluoro group as a H-bonding handle to ‘lock’ that axis into the trans conformation. This seemingly simple modification led to a dramatic increase in HER selectivity, particularly towards HER4, a kinase with emerging implications in ovarian cancer.
Excited to share our new ChemRxiv preprint:
“Leveraging Conformational Control of Neratinib’s C–N Axes to Enhance HER4 Selectivity in Ovarian Cancer”
congrats to the tam @StonyBrookChem and @SDSUChemBiochem
Read here: https://t.co/0gyoBcOgUc
The ‘conformational mapping’ of diarylamine crystal structures suggested that the pan-HER kinase inhibitor neratinib adopts two planar conformations around a C–N axes (similar to cis and trans alkenes). HER family kinases generally preferred the ‘trans’ conformation
I am sharing this preprint from my group. Inspired by all the great recent skeletal editing work, we developed an atropisomer selective strategy to take Indoles to quinolines. https://t.co/0QbvvTBSmn...
Our department (@StonyBrookChem) is looking for a PRODiG+ fellow – the appointment is two years, followed by conversion to a tenure-track assistant professor at the conclusion of the fellowship. A unique opportunity!
https://t.co/eQwXVBmTdc
The Stony Brook Chemistry Department is searching for a Chemical Biologist at the Associate or Full professor Level. Come join us on Long Island and do some great science! https://t.co/rdDzReWL0s
Check out our latests work in collaboration with @Taylorlab_Chem ! We evaluated their biomolecular photocaged trifluormethylation reagent on small molecules, finding it effected the rapid trifluoromethylation of diverse aromatics, including several APIs.
https://t.co/lS1020lIrA
The Stony Brook Chemistry Department is searching for a Chemical Biologist at the Associate or Full professor Level. Come join us on Long Island and do some great science! https://t.co/rdDzReWL0s